Profile data is unavailable for this security.
About the company
Suzhou Zelgen Biopharmaceuticals Co Ltd is a China-based company mainly engaged in pharmaceutical manufacturing. The Company's main products include pharmaceuticals and pharmaceutical intermediates and raw materials. Its products are mainly applied in the fields of tumors, bleeding and blood diseases, immune inflammatory diseases and hepatobiliary diseases. The Company operates in the domestic market and overseas markets.
- Revenue in CNY (TTM)742.28m
- Net income in CNY-133.34m
- Incorporated2009
- Employees910.00
- LocationSuzhou Zelgen Biopharmaceuticals Co LtdNo. 209, Chenfeng Road, Kunshan CitySUZHOU 215300ChinaCHN
- Phone+86 51 257011882
- Fax+86 51 257018306
- Websitehttps://www.zelgen.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tasly Pharmaceutical Group Co Ltd | 8.35bn | 1.10bn | 22.35bn | 10.96k | 20.36 | 1.82 | -- | 2.68 | 0.7348 | 0.7348 | 5.59 | 8.24 | 0.525 | 1.83 | 7.50 | 761,658.60 | 6.44 | 5.86 | 7.91 | 7.26 | 65.70 | 58.62 | 12.26 | 10.61 | 3.12 | -- | 0.0642 | 56.80 | -2.03 | -14.86 | -10.78 | -0.9327 | -5.02 | 9.94 |
| Bloomage Biotechnology Corp Ltd | 4.66bn | 64.62m | 23.55bn | 4.44k | 350.69 | 3.31 | -- | 5.06 | 0.1394 | 0.1394 | 9.59 | 14.76 | 0.5431 | 1.12 | 8.61 | 1,048,475.00 | 0.719 | 8.43 | 0.827 | 9.97 | 70.71 | 75.45 | 1.32 | 12.34 | 1.42 | 40.02 | 0.0317 | 30.32 | -11.61 | 23.29 | -70.59 | -21.53 | 9.89 | -21.54 |
| Zhejiang Huahai Pharmaceutical Co., Ltd. | 8.71bn | 468.07m | 24.17bn | 9.07k | 49.57 | 2.54 | -- | 2.77 | 0.3256 | 0.3256 | 6.00 | 6.35 | 0.4279 | 0.9611 | 3.17 | 960,689.80 | 2.18 | 5.67 | 3.15 | 7.93 | 59.76 | 60.79 | 5.10 | 11.66 | 0.7399 | 8.95 | 0.4519 | 31.74 | 14.91 | 12.12 | 34.74 | 14.46 | 18.47 | 6.58 |
| Hubei Jumpcan Pharmaceutical Co Ltd | 6.14bn | 1.65bn | 25.06bn | 5.03k | 15.12 | 1.81 | -- | 4.08 | 1.80 | 1.80 | 6.69 | 15.02 | 0.3543 | 2.99 | 3.59 | 1,222,407.00 | 9.53 | 15.19 | 11.67 | 19.57 | 75.44 | 81.73 | 26.91 | 26.02 | 5.18 | -- | 0.0437 | 46.90 | -16.96 | 2.93 | -10.32 | 9.30 | -20.43 | 11.19 |
| Suzhou Zelgen Biopharmaceuticals Co Ltd | 742.28m | -133.34m | 25.40bn | 910.00 | -- | 22.10 | -- | 34.22 | -0.5038 | -0.5038 | 2.80 | 4.34 | 0.2482 | 0.446 | 4.77 | 815,689.40 | -4.56 | -17.15 | -8.23 | -25.89 | 89.95 | 93.14 | -18.36 | -118.33 | 1.72 | -- | 0.4949 | -- | 37.91 | -- | 50.52 | -- | 44.66 | -- |
| Kangmei Pharmaceutical Co Ltd | 5.28bn | 16.64m | 26.69bn | 4.23k | 1,678.26 | 3.71 | -- | 5.06 | 0.0012 | 0.0012 | 0.3973 | 0.5197 | 0.3785 | 1.64 | 2.23 | 1,246,204.00 | 0.1368 | -21.82 | 0.2232 | -42.17 | 17.12 | -92.73 | 0.3614 | -108.18 | 0.7875 | -- | 0.0162 | -- | 6.47 | -14.63 | -91.64 | -- | -33.46 | -- |
| Xiamen Amoytop Biotech Co Ltd | 3.34bn | 939.58m | 28.11bn | 2.42k | 29.81 | 9.31 | -- | 8.41 | 2.31 | 2.31 | 8.22 | 7.40 | 1.03 | 0.8127 | 4.99 | 1,379,284.00 | 29.05 | 22.72 | 33.93 | 26.54 | 92.37 | 91.62 | 28.11 | 23.51 | 3.20 | -- | 0.0448 | 28.80 | 34.13 | 31.02 | 49.00 | 66.70 | 41.17 | 90.06 |
Data as of Feb 11 2026. Currency figures normalised to Suzhou Zelgen Biopharmaceuticals Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
44.29%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| China Universal Asset Management Co., Ltd.as of 30 Jun 2025 | 14.26m | 8.48% |
| Fullgoal Fund Management Co., Ltd.as of 30 Jun 2025 | 13.87m | 8.25% |
| Zhong Ou Asset Management Co., Ltdas of 30 Jun 2025 | 11.14m | 6.63% |
| GF Fund Management Co., Ltd.as of 30 Jun 2025 | 10.53m | 6.26% |
| ICBC UBS Asset Management Co. Ltd.as of 30 Jun 2025 | 8.38m | 4.99% |
| JPMorgan Asset Management (China) Co Ltd.as of 30 Jun 2025 | 4.26m | 2.53% |
| China Southern Asset Management Co., Ltd.as of 30 Jun 2025 | 3.29m | 1.96% |
| China Asset Management Co., Ltd.as of 30 Jun 2025 | 3.24m | 1.93% |
| Bosera Asset Management Co., Ltd.as of 30 Jun 2025 | 2.83m | 1.68% |
| Yinhua Fund Management Co., Ltd.as of 30 Jun 2025 | 2.66m | 1.58% |
More ▼
Data from 30 Jun 2025 - 05 Feb 2026Source: FactSet Research Systems Inc.
